Query String: axitinib
AG-013736 US9205078, Axitinib US9617222, Compound A AXITINIB US10464902, Axitinib BDBM25117 N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide US20250129067, Compound Axitinib
- Z′-LYTE Screening Assay Axitinib was tested using a Z′-LYTE Screening Protocol (Invitrogen, Carlsbad, Calif.). Axitinib was prepared in 100% DMSO, and added to the reaction for a final DMSO concentration of 1%. Inhibitor concentrations varied from 1.0 μM to 0.00003 μM. Typical reactions were 10 μL, contained ABL1 or ABL1 [T315I], ATP (ABL1; 10 μM and ABL1 [T315I]; 5 μM), 2.0 μM Tyr 02 peptide, 10 mM MgCl2, 1.0 mM EGTA, 0.01% BRIJ-35, 1% DMSO in 50 mM HEPES pH 7.5. The mixture was incubated in a 384-well polypropylene plate at room temperature for an hour and terminated by the addition of 5 μL of a 1:64 dilution of the development reagent utilized with Z′-LYTE Screening Protocol, followed by a 30 second shake.
- ABL1 Kinase Mobility-Shift Assay Axitinib was tested with the Caliper LabChip3000 assay (Caliper Life Science, Hopkinton, Mass.), which is a mobility-shift assay (MSA) that combines the basic principles of capillary electrophoresis in a micro-fluidic environment. Axitinib was prepared in 100% DMSO, diluted to 25% DMSO with 20 mM HEPES pH 7.5, and added to the reaction for a final DMSO concentration of 6%. Inhibitor concentrations varied from 1.0 uM to 0.00003 uM. Typical reactions were 20 uL, contained ABL1 or ABL1 [T315I], ATP (ABL1; 25 uM and ABL1 [T315I]; 5 uM), 1.0 uM ABLtide, 5 mM MgCl2, 2 mM DTT, 0.01% Triton X-100 (Sigma-Aldrich, St. Louis, Mo.), 6% DMSO in 20 mM HEPES pH 7.5. The mixture was incubated in a 384-well polypropylene plate at room temperature for an hour and terminated by the addition of 60 uL of QuickScout Screening Assist MSA Buffer (Carna Biosciences, Kobe, Japan).